Clazakizumab shows promise in psoriatic arthritis

A new drug called clazakizumab has performed well in a study of people with psoriatic arthritis, according to results published in Arthritis & Rheumatology.

Clazakizumab is an anti-interleukin-6 monoclonal antibody.

A total of 165 people with active psoriatic arthritis who hadn’t responded to non-steroidal anti-inflammatory drugs were split into groups. One group was given a pretend drug and the others were given clazakizumab (25mg, 100mg or 200mg every four weeks) with or without methotrexate.

The results showed that clazakizumab was well-tolerated and may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis but more work is needed to confirm the appropriate dose.

Click here to read the original study.